Amiodarone-induced thyrotoxicosis is a form of iatrogenic hyperthyroidism that develops during amiodarone therapy or even after its discontinuation, owing to the prolonged tissue persistence of the drug and its metabolites. Amiodarone is an iodine-rich antiarrhythmic drug structurally related to thyroid hormones; a 200 mg dose provides approximately 75 mg of organic iodine, with daily release of quantities of iodide that greatly exceed usual dietary intake. Against this background, thyrotoxicosis may result either from an iodine-induced increase in hormone synthesis in a predisposed thyroid gland or from a destructive thyroiditis with release of preformed hormones from damaged thyrocytes. Distinguishing between these mechanisms is not merely academic, because it determines the choice of treatment and the expected time to response.
The clinical relevance of amiodarone-induced thyrotoxicosis is amplified by the cardiological context: it often affects patients with complex arrhythmias, structural heart disease or heart failure, in whom even a moderate excess of thyroid hormones may precipitate tachyarrhythmias, cardiac decompensation or ischemia. Management therefore requires an integrated endocrinological and cardiological strategy, with the simultaneous objectives of hemodynamic stabilization, control of hormone production or release, and carefully considered decisions regarding continuation of amiodarone.
The epidemiology of amiodarone-induced thyrotoxicosis depends on variables including the iodine status of the population, the prevalence of pre-existing thyroid disease and the characteristics of the treated cardiological cohort. In practical terms, the observed frequency varies considerably between iodine-sufficient areas and areas of relative iodine deficiency, because the same pharmacological iodine excess may have different effects on a thyroid gland rendered vulnerable by latent nodular autonomy. Moreover, the exposed population is not representative of the general population: amiodarone is prescribed primarily for potentially serious arrhythmias and therefore often to older patients with comorbidities and polypharmacy, in whom recognition of symptoms may be more difficult and the clinical impact more severe.
The main risk factors include the presence of pre-existing or latent thyroid disease. A multinodular goiter, a subclinical toxic adenoma or a history of thyroid dysfunction increases the likelihood that iodine excess will trigger hormone overproduction. In these settings, thyrotoxicosis often represents the unmasking of functional autonomy made clinically apparent by the massive iodine load. Certain ultrasonographic features, such as nodularity and increased thyroid volume, may also indicate a predisposing background.
A second risk pathway concerns the individual response and the vulnerability of thyroid tissue to the direct effects of amiodarone. The drug and its metabolite may exert cytotoxic and pro-inflammatory effects on thyrocytes, promoting destructive thyroiditis even in the absence of known thyroid disease. This category includes patients whose thyroid gland appeared normal before treatment and in whom thyrotoxicosis is more commonly related to the release of preformed hormones and intrathyroidal inflammation.
Duration of exposure and cumulative dose influence risk, but not in a linear manner, because the long half-life and tissue accumulation make late onset possible, even after discontinuation of the drug. This aspect is clinically crucial: thyrotoxicosis in a patient who discontinued amiodarone several months earlier remains compatible with an amiodarone-related etiology, and the medication history must therefore extend sufficiently far back in time rather than being limited to recent treatments.
Other factors that modulate risk include advanced age, cardiovascular comorbidities and concomitant exposure to iodinated contrast media or other sources of iodine, which may add to the overall iodine load. However, the most clinically important element is not the presence of a single factor, but the combination of thyroid vulnerability and cardiac frailty, because this combination determines the likelihood that thyrotoxicosis will result in major clinical events such as difficult-to-control atrial fibrillation, worsening heart failure or a reduced ischemic threshold.
Amiodarone-induced thyrotoxicosis encompasses distinct mechanisms that converge on the same biochemical phenotype of thyroid hormone excess. The first mechanism is iodine-induced hormone overproduction in a predisposed thyroid gland, often referred to as type 1 disease. In this setting, the massive iodine load overcomes the normal autoregulatory mechanisms and promotes the synthesis of T4 and T3 in autonomous tissue or a multinodular goiter, where regulation by TSH has already been partially bypassed. This effect is facilitated by the fact that amiodarone provides pharmacological quantities of iodine over a prolonged period, thereby maintaining the availability of substrate for hormone synthesis.
A second mechanism, often referred to as type 2 disease, is a drug-induced destructive thyroiditis in which thyrocyte injury causes the release of preformed hormones and thyroglobulin into the circulation, producing a pattern resembling subacute thyroiditis but without necessarily causing cervical pain. In this case, the thyroid gland is not stimulated to produce more hormone, but instead releases stored hormones as a result of cell lysis. This explains why antithyroid treatment that blocks hormone synthesis may be poorly effective when used alone, whereas glucocorticoids, by reducing inflammation and tissue injury, may accelerate control of the condition.
Clinical practice also recognizes mixed or indeterminate forms, in which increased synthesis and destructive processes coexist or in which the available markers do not allow a clear classification. This may occur because a nodular thyroid gland may simultaneously be exposed to a cytotoxic insult, or because the initial phase may present overlapping characteristics. The pathophysiology is further complicated by the systemic effects of amiodarone on peripheral thyroid hormone metabolism: the drug inhibits peripheral deiodinases, alters the relationship between T4, T3 and rT3, and may modify the interpretation of laboratory tests during the early stages, making assessment more complex unless it is integrated with the clinical context.
From a hemodynamic perspective, thyroid hormone excess increases sensitivity to catecholamines and myocardial oxygen demand, while reducing peripheral vascular resistance and increasing cardiac output. In patients with heart disease, these effects may destabilize arrhythmias and precipitate heart failure. At the same time, increased energy turnover and proteolysis promote loss of muscle mass and frailty, while accelerated bone turnover increases bone resorption and osteometabolic risk if the condition persists. The combination of the thyroid mechanism and cardiac vulnerability is therefore the key pathophysiological factor explaining the high clinical severity of amiodarone-induced thyrotoxicosis compared with other causes of thyrotoxicosis associated with comparable hormone levels.
A final pathogenetic consideration concerns the persistence of the drug: the lipophilic nature of amiodarone results in its accumulation in adipose and muscle tissue and in a long half-life, with prolonged iodine release even after discontinuation. Consequently, the underlying pathophysiology may remain sustained over time, and the decision to discontinue or continue amiodarone does not have an immediate effect on the available iodine load. It may, however, influence the medium-term course and, most importantly, the patient’s arrhythmic risk.
The clinical presentation of amiodarone-induced thyrotoxicosis may be attenuated or atypical because amiodarone has antiadrenergic and conduction-slowing properties that may mask classic signs such as marked tachycardia or obvious tremor. For this reason, the medical history must be particularly thorough in reconstructing recent changes in functional status, especially in patients with complex cardiac disease. The most commonly reported symptoms include worsening exercise intolerance, fatigue, dyspnea, weight loss, insomnia and irritability. In some cases, the patient primarily notices an otherwise unexplained worsening of cardiac symptoms, with increased palpitations or recurrence of previously controlled arrhythmias.
In many cases, the most clinically relevant manifestation is cardiovascular destabilization: an increased frequency of atrial fibrillation episodes, greater difficulty controlling ventricular rate, increased ectopic activity or worsening heart failure. In older or frail patients, hyperthyroidism may present with a paucisymptomatic phenotype dominated by asthenia, weight loss and functional decline, while autonomic manifestations may be less evident. This oligosymptomatic presentation is particularly insidious because it delays diagnosis and increases the risk of complications.
On physical examination, findings may include warm, moist skin, fine tremor, hyperreflexia and loss of muscle mass, although cardiopulmonary findings such as an irregular rhythm, signs of congestion or reduced exercise tolerance often predominate. Examination of the neck may reveal a nodular or multinodular goiter if a predisposing thyroid substrate is present, whereas in destructive forms the thyroid gland may remain normal in size. The absence of cervical pain does not exclude a thyroiditic component, and the presence or absence of goiter alone is insufficient to classify the type of disease.
From a laboratory perspective, abnormalities such as reduced cholesterol levels, worsening glycemic control and increased bone turnover may occur. However, these findings are nonspecific and are often confounded by the cardiological and pharmacological context. The greatest clinical risk remains progression to acute heart failure or a severe systemic condition, potentially culminating in complicated thyrotoxicosis in a patient with limited cardiac reserve. In this setting, the threshold for urgent assessment must be low, because hemodynamic stability may deteriorate rapidly even when the initial symptoms are subtle.
Amiodarone-induced thyrotoxicosis should be suspected whenever a patient currently receiving amiodarone, or who received it in the recent or more distant past, develops clinical deterioration compatible with thyroid hormone excess or otherwise unexplained cardiac destabilization. In practice, suspicion should be particularly high in cases of recurrent or worsening atrial fibrillation, sudden difficulty controlling ventricular rate, worsening heart failure or a reduced ischemic threshold, especially when these features are associated with weight loss and increasing asthenia.
Suspicion should also remain high when the presentation is atypical. An older patient with functional decline, weight loss, irritability and insomnia, but without marked tachycardia, may still be thyrotoxic because amiodarone can attenuate adrenergic signs. In these cases, the most common error is to attribute the symptoms to progression of the underlying heart disease or to comorbidities without systematically reassessing thyroid function. The clinician must therefore always integrate the medication history and chronology of exposure, remembering that thyrotoxicosis may develop even after discontinuation because of the prolonged persistence of the drug.
Another relevant scenario is the presence of a known nodular goiter or pre-existing thyroid disease. In these patients, the pharmacological iodine load makes a hypersecretory form more likely. However, the absence of a history of thyroid disease does not exclude the diagnosis, because destructive forms may occur in an apparently normal thyroid gland. In summary, suspicion should be guided by the combination of amiodarone exposure and a discrepancy between the expected clinical stability and the observed cardiometabolic deterioration, with a low diagnostic threshold in patients with significant heart disease.
The diagnosis of amiodarone-induced thyrotoxicosis requires a sequential approach that confirms biochemical thyrotoxicosis and, most importantly, identifies the predominant mechanism in order to guide treatment. The first step is to document suppressed TSH with increased FT4 and/or FT3. During amiodarone therapy, interpretation of thyroid function tests must take into account the drug’s effects on peripheral hormone conversion and hormone patterns. FT4 and FT3 should therefore be assessed together, and the results should be correlated with the clinical presentation and temporal trends rather than interpreted on the basis of a single blood sample. In unstable patients, clinical stabilization remains the priority, but laboratory confirmation must be obtained rapidly to allow specific treatment to be initiated.
Once thyrotoxicosis has been confirmed, the objective is to distinguish iodine-induced hormone overproduction from a destructive form. Thyroid ultrasonography with color Doppler is often a key investigation: increased vascularity and a pattern consistent with hyperfunction support increased hormone synthesis, whereas reduced or non-increased vascularity in a non-nodular thyroid gland makes destructive thyroiditis more likely. Ultrasonography also allows the identification of nodules or a multinodular goiter, findings that support the presence of a substrate predisposing to hormone overproduction.
Thyroid scintigraphy with assessment of radioactive iodine uptake may be helpful, but its usefulness is limited by the high iodine load, which often reduces uptake even in hypersecretory forms. Despite this limitation, markedly reduced uptake in a compatible clinical setting may support a destructive component, whereas uptake that is not completely suppressed, when present, may suggest increased hormone synthesis. In some centers, alternative tracers or additional functional techniques may contribute to the assessment, but the central element remains integration of ultrasonographic findings, the clinical presentation and the response to treatment.
Immunological markers may be useful in the differential diagnosis. The presence of antibodies associated with thyroid autoimmunity does not independently identify amiodarone-induced thyrotoxicosis, but may indicate a predisposing background or concomitant disease. Measurement of TRAb, when positive, instead suggests concomitant Graves disease, a possible and clinically relevant scenario. Inflammatory parameters and markers such as interleukins have been proposed in some case series, but their specificity in clinical practice is limited and they do not replace morphological and functional assessment of the thyroid gland.
In addition to determining the thyroid etiology, the cardiac impact must be assessed. An ECG is essential for identifying arrhythmias and guiding management. In patients with heart failure or severe symptoms, cardiological assessment is part of the clinical evaluation of disease severity because it determines the required treatment intensity and the potential need for hospitalization or continuous monitoring. In many cases, a definitive diagnosis is constructed through an integrated approach comprising biochemical confirmation, compatible instrumental findings and clinical consistency in a patient exposed to amiodarone, followed by indirect confirmation based on the course observed during targeted treatment.
The most clinically useful classification of amiodarone-induced thyrotoxicosis distinguishes a form caused by increased hormone synthesis, often referred to as type 1, from a destructive form, referred to as type 2, with an intermediate category comprising mixed or indeterminate forms. The hypersecretory form is more likely in patients with a multinodular goiter, latent functional autonomy or pre-existing thyroid disease. It is driven by the massive availability of iodine, which fuels hormone synthesis, and may be associated with increased thyroid vascularity on Doppler ultrasonography. The destructive form is more likely in patients with a previously normal thyroid gland, ultrasonographic signs of inflammation and no increased vascularity, and reflects thyrocyte injury with release of preformed hormones.
Mixed forms represent a continuum and are clinically relevant because they often require combined treatment, particularly when clinical severity requires rapid control and it is not possible to await the natural course of the disease or a definitive classification. In these cases, the approach is based on pre-test probability, ultrasonographic findings and the response during the first days or weeks of treatment, which may provide information about the predominant mechanism.
Clinical severity must be classified in parallel with the etiopathogenetic type, because the therapeutic priority is often determined by cardiac risk. Moderate thyrotoxicosis in a patient with advanced heart failure or unstable arrhythmias is clinically more severe than biochemically more pronounced thyrotoxicosis in a young patient without heart disease. For this reason, clinically useful classification also includes assessment of hemodynamic instability, arrhythmias, heart failure, rapid weight loss and inability to take oral medication, all of which may require hospitalization, continuous monitoring and earlier definitive strategies such as surgery.
Treatment of amiodarone-induced thyrotoxicosis must pursue two simultaneous objectives: rapidly reducing the cardiovascular effects of thyroid hormone excess and acting on the thyroid mechanism sustaining the thyrotoxicosis. Management is therefore necessarily multidisciplinary. The initial level of treatment often consists of stabilization, with control of adrenergic symptoms and arrhythmia using beta-blockers when appropriate and dedicated cardiological strategies according to the patient’s clinical profile. Specific endocrinological treatment is initiated concurrently and differs according to the disease type.
In forms caused by increased hormone synthesis, the main treatment consists of antithyroid drugs such as methimazole, often at higher doses than those used for other forms of hyperthyroidism because the iodine-saturated thyroid gland may be relatively resistant. In selected settings and for limited periods, the addition of perchlorate may be useful to reduce iodide uptake by the thyroid gland and improve the effectiveness of antithyroid treatment. This combination requires rigorous balancing of benefits and safety and close monitoring, because the objective is to achieve more rapid control in situations where cardiac risk does not permit prolonged delays.
In destructive forms, the most effective treatment is often represented by glucocorticoids, which reduce inflammation and thyrocyte injury and accelerate resolution of hormone release. In this setting, antithyroid drugs are less useful when administered alone because increased synthesis is not the predominant mechanism. A clinical and biochemical response to glucocorticoids, when present, also provides indirect confirmation of the destructive component and guides gradual dose reduction according to the clinical and laboratory course.
In mixed or indeterminate forms, or when severity requires a broad initial approach, combined treatment with antithyroid drugs and glucocorticoids is often used, with the possible addition of perchlorate in selected cases. The objective is to reduce hormone excess rapidly by acting on both synthesis and release, thereby preventing an initial classification error from delaying effective treatment. The decision to continue or discontinue amiodarone must be individualized. In some patients, discontinuation is not possible because of arrhythmic risk, and stopping the drug does not provide an immediate benefit because of its long half-life. However, when an alternative antiarrhythmic strategy is feasible and cardiac risk can be controlled, discontinuation may contribute to medium-term disease control and reduce the likelihood of recurrence.
When thyrotoxicosis is refractory to medical treatment, when the patient is hemodynamically unstable or when rapid and definitive control is required, total thyroidectomy represents a decisive option. Surgery in these patients requires expert preparation and perioperative management, but it may be lifesaving in resistant or complicated cases. Definitive treatment with radioiodine is often ineffective in the short term because thyroid uptake is generally reduced by the iodine load, making radioiodine impractical during the active phase. It may become a consideration only in selected circumstances and after appropriate preparation, when uptake is sufficient.
Follow-up of amiodarone-induced thyrotoxicosis must be structured on two levels: endocrinological monitoring of the response and cardiological monitoring of clinical stability, because reduction of thyroid hormone excess does not always coincide with immediate recovery from cardiac decompensation. During the initial phase, monitoring of FT4 and FT3 is more informative than TSH, which may remain suppressed for several weeks. Testing should be performed at shorter intervals in severe forms or in patients at high cardiac risk and should be adapted to the treatment strategy, because antithyroid drugs, glucocorticoids and combined treatment require different periods before producing a meaningful change.
During treatment with antithyroid drugs, follow-up must include clinical and laboratory assessment of both efficacy and safety, with attention to symptoms that may indicate significant adverse events. During glucocorticoid treatment, benefits and risks must be carefully balanced by monitoring metabolic parameters, blood pressure and tolerability, particularly in frail patients or those with diabetes, and by planning a gradual dose reduction consistent with the clinical response. In mixed forms, follow-up must confirm that hormone levels are moving in the expected direction. If the response is inadequate, the classification and therapeutic strategy should be reconsidered promptly, including definitive options.
From the cardiological perspective, follow-up must monitor heart rhythm, heart rate and signs of heart failure. Even partial improvement in thyrotoxicosis may reduce the arrhythmic burden, but some patients retain residual risk requiring medication adjustments and reassessment of the antiarrhythmic strategy. In this context, the decision to continue amiodarone must be reassessed over time in light of the thyroid control achieved and the availability of alternatives, without automatic decisions but with a realistic assessment of both recurrence risk and arrhythmic risk.
An essential component of follow-up is long-term surveillance of thyroid function, because hypothyroidism may develop after the thyrotoxic phase, particularly in destructive forms, requiring prompt recognition and initiation of levothyroxine when indicated. The thyroid course may therefore progress through several phases, and follow-up must be sufficiently prolonged to detect this transition, avoiding both extended periods of untreated dysfunction and excessive correction that could once again destabilize the cardiac condition.
The prognosis of amiodarone-induced thyrotoxicosis depends critically on the patient’s cardiac reserve, the speed with which thyroid hormone excess is controlled and the etiopathogenetic type. Destructive forms may resolve over time with appropriate treatment, but may be dangerous during the active phase because of their cardiovascular effects and the possibility of progression to hypothyroidism. Hypersecretory forms tend to require more complex and prolonged treatment, with a greater risk of relative refractoriness to antithyroid drugs because of iodine saturation, and may sometimes require definitive strategies to achieve long-term stability.
The most clinically relevant complications are cardiovascular: atrial fibrillation with hemodynamic instability, worsening heart failure, myocardial ischemia and reduced exercise tolerance. In patients with ventricular arrhythmias or advanced heart disease, thyrotoxicosis may precipitate major events requiring intensive management. Another important complication is the therapeutic difficulty associated with the need to continue amiodarone in some patients. Persistence of the drug prolongs the period of risk and may promote recurrence or extend the duration of thyroid dysfunction.
From an endocrinological perspective, a frequent complication during the clinical course is progression to hypothyroidism, which may develop after the destructive phase or following definitive treatment. Hypothyroidism is not a minor complication in cardiac patients because an excessively low thyroid state may worsen cardiac function and the lipid profile. Correction must therefore be prompt but cautiously titrated. Metabolic complications include loss of muscle mass, worsening glycemic control and accelerated bone turnover, with increased osteometabolic risk if the condition persists.
Treatment-related complications include adverse effects of antithyroid drugs and the systemic impact of glucocorticoids, particularly when used at substantial doses and for extended periods. In refractory cases, surgery carries a perioperative risk determined mainly by the severity of the underlying cardiac disease and by the need to operate in the presence of instability or incomplete hormonal control. Despite these challenges, a timely, structured and integrated care pathway allows satisfactory clinical control to be achieved in most cases and substantially reduces the risk of major acute events.